Haemonetics Corp (FRA:HAZ)
€ 78.5 -0.5 (-0.63%) Market Cap: 3.97 Bil Enterprise Value: 4.85 Bil PE Ratio: 34.58 PB Ratio: 4.78 GF Score: 28/100

Haemonetics Corp at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 03:05PM GMT
Release Date Price: €112.64 (-3.58%)
David Ryan Lewis
Morgan Stanley, Research Division - MD

Okay. So let's get going. We're getting kind of a late start here. My apologies. My name is David Lewis, medical device analyst from Morgan Stanley. It's my pleasure to have with me this morning Haemonetics Corporation as we progress through the morning, and their CEO, Chris Simon.

Questions & Answers

David Ryan Lewis
Morgan Stanley, Research Division - MD

We're going to jump right into it. And Chris, there is -- I think I may not -- I don't think I've ever see a more rapid transformation of a business for a mid-cap medical device company than we've seen at Haemonetics. Frankly, since you joined, we've seen growth acceleration, really transformative costs. So the question, and we talked about a little bit of this in our CEO call a few months back, but what's next for you in terms of what's the next phase of transformation at Haemonetics?

Christopher Simon
Haemonetics Corporation - CEO, President & Director

Yes. Thanks, David. I appreciate the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot